



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : G01N 33/487, 33/50, 33/539, 33/573</p>	A1	<p>(11) International Publication Number: WO 00/31531</p> <p>(43) International Publication Date: 2 June 2000 (02.06.00)</p>
<p>(21) International Application Number: PCT/BR99/00096</p> <p>(22) International Filing Date: 23 November 1999 (23.11.99)</p> <p>(30) Priority Data: PI 9804648-9 23 November 1998 (23.11.98) BR</p> <p>(71) Applicant (for all designated States except US): FUNDAÇÃO OSWALDO CRUZ - FIOCRUZ [BR/BR]; Avenida Brasil, 4365, Manguinhos, CEP-21045-900 Rio de Janeiro, RJ (BR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): FILHO, Milton, Ferreira [-/BR]; Avenida Brasil, 4365, Manguinhos, CEP-21045-900 Rio de Janeiro, RJ (BR). LUZIA, Vera, Lúcia [-/BR]; Avenida Brasil, 4365, Manguinhos, CEP-21045-900 Rio de Janeiro, RJ (BR). BARROSO, Eduardo, Werneck [-/BR]; Avenida Brasil, 4365, Manguinhos, CEP-21045-900 Rio de Janeiro, RJ (BR). GEMAL, André, Luis [-/BR]; Avenida Brasil, 4365, Manguinhos, CEP-21045-900 Rio de Janeiro, RJ (BR).</p> <p>(74) Agent: BHERING, João, R., V.; Bhering, Almeida & Associados, Rua Beneditinos, 16, 11 andar, CEP-20081-050 Rio de Janeiro, RJ (BR).</p>		<p>(81) Designated States: CA, US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: MONITORING PATIENT COMPLIANCE AND BIOAVAILABILITY OF DRUGS BY DEPROTEINIZING BODY FLUIDS</p>		
<p>(57) Abstract</p> <p>The present invention is a method for drug level detection by using a simplified and effective deproteinizing step from body fluids, such as plasma, blood, urine, saliva, tear fluid, followed by drug extraction and measurement using an accurate technique, such as a colorimetric assay or a High-Performance Liquid Chromatography method. In a particular embodiment, the invention is directed to a method to quantify rifampicin in order to monitor its levels in body fluids and also to a Kit for rifampicin concentration measurement.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: **MONITORING PATIENT COMPLIANCE AND BIOAVAILABILITY OF
DRUGS BY DEPROTEINIZING BODY FLUIDS**

The present invention relates to methods of determining the concentration of a selected drug in the body of a subject to provide the monitoring of either drug levels in a clinical setting and in public health services and patient compliance with medication prescriptions. The methods are characterized by a simplified and effective deproteinizing body fluid step followed by drug extraction and measurement using an accurate technique, such as a colorimetric assay or a High-Performance Liquid Chromatography method.

BACKGROUND OF THE INVENTION

In the field of medicine, a number of medications have been found safe and efficacious for the treatment of patients with physical illnesses. Patients placed on prescribed medication treatment plans are typically monitored. Subjective and objective methods are used to identify bothersome symptoms and to implement any changes necessary during the course of treatment. Monitoring may continue for as long as treatment is provided.

Currently, the most common method of monitoring patients for medication compliance is clinical observation which involves individual counseling and close personal supervision by physicians which observe physiological signs and symptoms or residual signs of illness and also listen to patient complaints regarding degree of pain relief and evaluate

physiological changes over time. This method is time consuming, expensive and highly subjective. Needless to say, it is fraught with potential errors.

Additional compliance information can also be obtained using qualitative urine monitoring methods such as the standard laboratory procedure called enzyme-multiplied immunoassay (EMIT). Utilizing an arbitrary cutoff value, these methods provide the clinician with a simple positive or negative indication of the possible presence or absence of a parent drug or its metabolites in a patient's urine. The parent drug is the prescribed medication itself and the metabolites are those chemical derivatives of the medication which naturally occur upon the patient's body metabolizing the medication. These tests do not provide information concerning the time or amount of last drug use or whether or not the prescribed dose of medication was ingested properly, diverted or supplemented.

Physicians utilizing only clinical evaluation and qualitative urine drug screening test results may develop problems in their treatment methods. Consistently, Fox, W. (Fox, W. (1990). "Drug combinations and bioavailability of rifampicin". *Tubercle*. 71: 241-5) suggested parallel serum/plasma sampling in selected studies for testing abroad to verify the tuberculosis treatment effectiveness using drug combinations by confirming the urinary bioavailability determination. In the mentioned text, the term "abroad" means

outside developing countries in which expensive analytical equipment is not commonly found.

Another monitoring method sometimes used is a direct measurement of parent drug concentrations or active metabolites concentrations of the drug in plasma and other body fluids. This direct method presents some limitations since it is expensive and requires the use of time consuming and highly technical analytical procedures such as high-performance liquid chromatography and mass spectrometry since active and inactive metabolites must be quantified separately.

Attempts have been made to overcome the difficulties of the sophisticated analytical procedures. In the EP 122 032, it is described a method of determining the concentration of a selected drug in the body of a subject consisting of the steps of holding a liquid collecting means comprising an absorbent inert member, containing a reagent substance which reacts with selected drug, in a position in close proximity to an eye of the patient for collecting tear fluid therefrom and allowing the tear fluid collected to come into contact with said reagent substance during a period sufficient to permit the development of the reaction which has to be physically detectable. It is mentioned that this method provides a readily indication of the level of said drug in the body because the tear fluid is less complex than other

body fluids such as blood. Nevertheless, this assay permits only qualitative or semi-quantitative drug detection.

Although simplicity is an important quality when dealing with monitoring methods, the accuracy of the assay is crucial in the control of diseases, e.g. tuberculosis, specially to measure small quantities of drugs in complex body fluids, such as blood. In the US 4 656 141 it is proposed a high-performance liquid chromatography process for detecting the presence of trace amounts of non-fluorescent soluble compounds each having at least one labile hydrogen atom in a carrier solution by adding a non-fluorescent quinone which is reducible to a fluorescent hydroquinone, and irradiating the resulting solution in the absence of oxygen with light of sufficient energy to cause the quinone to be reduced to a hydroquinone.

Preferably both quantitative and analytical methods should be used to follow the patient on a repetitive basis to ensure that the patient is indeed ingesting the prescribed amounts of medication in the proper manner and responding as expected. Moreover, in control programmes of Public Health Services, confident monitoring of treatment is crucial. Tuberculosis Control Program may be cited as a representative example of this approach and Rifampicin as a highly potent drug widely used for tuberculosis treatment.

An efficient follow up the other drugs treatment performance is also important. Examples are anti-retroviral

drugs, such as proteinase or reverse transcriptase inhibitors, e.g. 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC) or 3'-azido-2,3'-dideoxythymidine (AZT) (see Frijus-Plessen N., Michaelis H.C., Foth H. e Kahl G.F. (1990). "Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography". Chrombio. Elsevier Science Publishers B.V. Amsterdam. 534: 101-107), anti-fungal drugs, e.g. itraconazole which is also used in anti-leishmanial chemotherapy (Anon: British Society for Antimicrobial Chemotherapy Working Party: Laboratory monitoring of antifungal chemotherapy. The Lancet. Vol. 337. pp. 1577-1580. 1991) or antimonials, the most used anti-leishmanial drug (World Health Organization. Tropical Disease Research. Twelfth Programme Report. World Health Organization. Geneva. Switzerland. Pp 139.1995).

In the case of patients with tuberculosis, there has been increasing interest in the determination of serum levels of the main antituberculosis drugs, in particular the most used rifampicin medication. The usual methods for rifampicin assay are colorimetry, microbiology and high-performance liquid chromatography. In the beginning, microbiological assays were employed by using *Sarcina lutea* or *Staphylococcus aureus*. Examples are described in: Furesz S., Scotti, R., Pallanza R., Mapelli E. (1967). "Rifampicin: A new

rifampicin. III Absorption, distribution and elimination in man". *Arzneim-Forsch.* 17: 534-7; Boman, G. (1974). "Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicyclic acid or isoniazid". *Europ J Clin Pharmacol.* 7: 217-25; Dickinson, J.M., Aber, V.R., Allen, B.W., Ellard, A., Mitchison, D.A. (1974). "Assay of rifampicin in serum". *J Clin Path.* 27: 457-62; Buniva, G., Pagani, V., Carozzi, A. (1983). "Bioavailability of rifampicin capsules". *Int J Clin Pharmacol Therapy Toxicol.* 21: 404-9; Immanuel, C., Jayasankar, K., Narayana, A.S.L., Saema, G.R. (1985). "Self-induction of rifampicin metabolism in man". *Indian Med Res.* 82: 381-7. However, the precision of such methods is generally poorer than would be expected with HPLC methods.

Colorimetric methods are interesting under the point of view of easier accomplishing. The procedures of such methods are described in: Maggi, N., Furesz, S., Pallanza, R., Pelizza G. (1969). "Rifampicin desacetylation in the human organism". *Arzneim-Forsch.* 19: 651-4; Sunahara, S., Nakagawa, H. (1972). "Metabolic study and controlled clinical trials of rifampicin". *Chest.* 61: 526-32; Jeanes, C.W.L., Jessamine, A.G., Eidus, L. (1972). "Treatment of chronic drug-resistant pulmonary tuberculosis with rifampicin and ethambutol". *Canad Med Ass J.* 106: 884-8; Brechbuhler, S., Flueher, H., Riess, W. (1978). "The renal elimination of rifampicin as a function of the oral dose". *Arzneim-Forsch.* 28: 480-3; McConnell,

J.B., Smith, H., Davis, M., Williams, R. (1979). "Plasma rifampicin assay for an improved solvent extraction technique". Br J Clin Pharmac. 8: 506-7; Israili, Z.H., Rogers C.M., El-Attar, H. (1987). "Pharmacokinetics of antituberculosis drugs in patients". J Clin Pharmacol. 27: 5 78-83

High-Performance Liquid Chromatography (HPLC) has been used for separate determination of rifampicin and its metabolites. HPLC procedures are described in: Goucher, C.R., 10 Peters, J.H., Gordon, G.R., Murray, J.F., Ichikawa, W., Welch, T.M., Geiber, R.H. (1977). "Chemical and bacteriological assays of rifampicin, rifampicin-quinone and desacetyl-rifampicin". 12th U.S.-Japan Joint Conference on Leprosy. Boston. Ma. Sept 27-29, 1977. pp. 47-59; Lecaillon, 15 J.B., Febvre, N., Metayer, J.P., Souppart, C. (1978). "Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography". J Chromatogr. 145: 319-24; Ratti, B., Rosina-Parenti, R., Toselli A., Zerrili, L.F. 20 (1981). "Quantitative assay of rifampicin and its metabolite 25 desacetyl-rifampicin in human plasma by reversed-phase high-performance liquid chromatography". J Chromatogr. 225: 526-31; Guillaumant, M., Leclercq, M., Forbert, Y., Guise, B., Harf, R. (1982). "Determination of rifampicin, 25 desacetyl-rifampicin, isoniazid and acetylisoniazid by high performance liquid chromatography: Application to human serum

extracts, polymorphonucleocytes and alveolar macrophages". J Chromatogr. 232: 369-76; Acocella, G., Nonis, A., Gialdroni-Grassi, G., Grassi, C. (1988). "Comparative bioavailability of isoniazid, rifampicin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy". Am Rev Respir Dis. 138: 882-5; Ishii, M., Agata, H. (1988) "Determination of rifampicin and its main metabolites in human plasma". J Chromatogr. 426: 412-6; Nau, R., Prange, W.H., Menck, S., Kolenda, H., Visser, K., Seydel, J.K. (1992). "Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges". J Antimicrob Chemother. 29: 719-24; Chouchane, N., Barre, J., Toumi, A., Tillement, J.P., Benakis, A. (1995). "Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man". Eur J Drug Metab Pharmacokin. 20: 315-20.

While providing useful information relative to patient status and treatment compliance, the clinical monitoring methods described above, i.e. clinical interviews with patients, direct plasma drug measurement and qualitative urine drug screening, have distinct drawbacks which limit their usefulness in extended treatment programmes. Although being effective, the complex assays with many extraction steps, e.g. HPLC, require expensive equipment and specialized operating personnel and materials which are not easily found in small hospital centers or field laboratories, mainly in

developing countries. Moreover, the occurrence of losses during the extraction steps lead to lower drug concentrations, and consequently to wrong results.

Thus, it remains a need for methods of monitoring patient compliance without the above mentioned disadvantages of the known methods but having sensitivity and specificity sufficient to detect trace amounts of substances contained in complex body fluids. Such monitoring methods would help physicians both in prescribing adequate doses of medication and in monitoring patients to insure that they are ingesting the prescribed amounts. Accordingly, it is to the provision of such improved methods that the present invention is directed.

SUMMARY OF THE INVENTION

The object of the invention is to provide the monitoring of either drug levels in a clinical setting and in public health services and patient compliance with medication prescriptions. The drug levels monitoring is accomplished by quantitative assays which allow drug detection in body fluids down to 0.3 µg/ml. The method based on extraction of the drug from biological fluids is characterized by a prior deproteinizing step in conditions that at least 97% of the drug is recovered, i.e. by carrying out the deproteinizing step in the presence of ZnSO₄ it is possible to efficiently strip off the drug which became bound to proteins contained in the biological fluid. Noteworthy the method of the

invention is specially useful for a drug assay from blood which contains much more protein than other biological fluids such as urine, saliva, tear fluid.

One embodiment of the present invention is a method for drug level detection by using a simplified and effective deproteinizing step from body fluids, such as plasma, blood, urine, saliva, tear fluid, followed by drug extraction and measurement using an accurate technique, such as a colorimetric assay or a High-Performance Liquid Chromatography method.

In a particular embodiment, the invention is directed to a method to quantify rifampicin in order to monitor its levels in body fluids and also to a kit of tuberculosis diagnosis based on rifampicin concentration measurement.

15 BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the reproducibility and accuracy of the method of the present invention illustrated by HPLC chromatograms of synthetic mixtures of rifampicin with body fluids: (A) rifampicin in plasma at 25; 12,5; 6,25; 3,13 and 1,56 $\mu\text{g/ml}$; (B) various samples of rifampicin synthetic mixture in saliva at a concentration of 2.0 $\mu\text{g/ml}$; (C) various samples of rifampicin synthetic mixture in urine at a concentration of 18 $\mu\text{g/ml}$.

FIGURE 2 shows the reproducibility and accuracy of the method of the present invention illustrated by a HPLC chromatogram of a synthetic mixture of 2',3'-dideoxycytidine

(ddC), 2',3'-dideoxyinosine (ddI) and 3'-azido-2,3'-dideoxythymidine (AZT) with plasma at a concentration of 20 $\mu\text{g/ml}$.

FIGURE 3 shows the reproducibility and accuracy of the method of the present invention illustrated by a HPLC chromatogram of a synthetic mixture of itraconazole with plasma at concentrations of 20; 10; 5; 2,5; and 1,25 $\mu\text{g/ml}$.

FIGURES 4A and 4B illustrate a set of standard curves demonstrating that Beer's law is followed for the range of 0.39 to 25 $\mu\text{g/ml}$ of rifampicin in plasma, and the reproducibility of the method of the present invention by colorimetric measurements at 340 nm.

FIGURE 5 illustrates the usefulness of the method of the present invention in rifampicin pharmacokinetics studies, showing the variation of rifampicin plasma concentration at the indicated time intervals for two HIV positive patients with tuberculosis.

DETAILED DESCRIPTION OF THE INVENTION

In medication maintenance programs, the patient is initially prescribed by a medication and dose based on several factors. These ordinarily include the severity and duration of illness, amounts and types of medications previously used, previous medical history, patient sex, pregnancy status, patient weight and ingestion of other therapeutic medications. In certain instances, the pathogenic agent may develop a significant level of resistance to the

drug or therapeutic combinations and therefore a loss of sensitivity to the administered drug. In this respect, the regular intake of drugs is of great importance.

To determine compliance with the prescribed medication dose, random body fluid samples, e.g. urine or blood are obtained from the patient and parent drug and/or its metabolites concentration is measured. Consistently, antifungal drugs concentrations in blood are measured either to ensure adequate concentrations of the drug and to avoid unwanted side-effects caused by undue concentration (Anon: British Society for Antimicrobial Chemotherapy Working Party: Laboratory monitoring of antifungal chemotherapy. The Lancet. Vol. 337. pp. 1577-1580. 1991).

Particularly in the treatment of tuberculosis, the regular intake of drugs is of great importance. Indeed, to reach the goal of elimination of tuberculosis as a public health problem, it is important to provide control programmes with an efficient tool to follow up the treatment. This can be accomplished by methods developed to detect even minor amounts of the drug or its metabolites in the body fluids. Such tests should also be carried out in chemotherapeutic studies for assessment of the efficacy of new drugs or regimens, particularly if the drugs are not taken under direct supervision.

Although rifampicin, isoniazid, pyrazinamide and ethambutol are the most commonly used drugs for the treatment

of tuberculosis, rifampicin and isoniazid are considered the first-line choice antituberculosis agent. The rifampicins are antibiotics produced by the bacterium *Streptomyces mediterranei* and is an amphoteric substance which is soluble both in organic solvents and in acid pH water. Rifampicin is metabolized by the liver, especially during its first passage through the hepatoportal system, and its principal metabolite is 25-desacetylrifampicin. The pharmacokinetics of rifampicin varies with the age of the patient and is affected by impaired liver and kidney function. In such circumstances, therapeutic drug monitoring of rifampicin might be of value in optimizing the dose. It is excreted from the human body unaltered and as its metabolites, desacetyl-rifampicin being its principal metabolite. Most of the drug is eliminated in the bile (about 80%) and some by the kidneys.

Almost all known methods of determining rifampicin concentration in body fluids, e.g. microbiological, HPLC and colorimetric methods, need a number of prior extraction steps to separate rifampicin and its metabolites from the complex mixture. Such step plays an important role in the accuracy of the assay because it is necessary to strip off rifampicin and its metabolites which became bound to body fluid proteins. But, in these methods, the removing treatment of the interferent components demands time and results in losses of the analytes, i.e. rifampicin and particularly its metabolites which are present in very low concentrations.

According to the present invention just one extraction step is used as prior treatment before drug level detection. Aqueous zinc sulfate, an appropriate solvent and the body fluid to be analyzed are mechanically mixed, and after
5 centrifuging, the deproteinized supernatant phase is carefully recovered to determine drug and its metabolites concentrations.

The prior separation of proteins from the body fluid to permit interferences elimination before drug level analysis is
10 known. Accordingly, Frijus-Plessen described a deproteinizing step in an assay to determine the concentration of the anti-retroviral drugs ddI, ddC and AZT (see Frijus-Plessen N., Michaelis H.C., Foth H. e Kahl G.F. (1990). "Determination of
15 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography". Chrombio. Elsevier Science Publishers B.V. Amsterdam. 534: 101-107) .
The proteins contained in blood are precipitated by using a saturated ammonium sulfate solution. In fact, the salting out
20 of proteins is a well-known and frequently used method in protein purification. Scopes, R.K. (Scopes, R.K. Protein Purification Principles and Practice. Second Edition. Springer-Verlag. New York. Chapter 3. Pp 50. 1988) mention
25 that the most effective salts used as salting out agents are those with multiple-charged anions such as sulfate, phosphate and citrate. In addition, it is cited that the cation is

relatively less important, and even so monovalent ions should be used, with $\text{NH}_4^+ > \text{K}^+ > \text{Na}^+$ in precipitation effectiveness.

Despite these assertions we have now found that the separation of proteins from complex mixtures, such as blood or plasma, is not effective unless zinc sulfate is used. Indeed, the separation of the interferent proteins by precipitating them from the drug containing body fluid is not obtained when saturated ammonium sulfate solution is used in the deproteinizing step. Moreover, according to the invention, a relative low concentration of zinc sulfate is advantageously used. The concentration of the zinc sulfate solution may vary from 0.1M to 5M, and preferably from 0.2M to 1.0M.

Thus, the complete method for monitoring patient compliance and drugs bioavailability of the present invention comprises the following steps: (1) mixing and shaking mechanically the body fluid with aqueous zinc sulfate solution, an appropriate solvent and, optionally an anti-oxidizing agent to precipitate proteins and strip off bound drug; (2) centrifugating the mixture to obtain the separation of phases; (3) recovering the supernatant which is used for the drug concentration measurement using an accurate technique, such as a colorimetric assay or a High-Performance Liquid Chromatography method.

The solvent used in the deproteinizing step are known and depends on the solubility properties of the drug which is

being measured. In the case of rifampicin and its metabolites, despite acetonitrile/2-propanol (1:1) is preferred, several organic solvents can be used such as benzene, toluene, dichloromethane, chloroform or its mixtures. For antimonials, itraconazole and proteinase or the reverse transcriptase inhibitors, such as 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC) or 3'-azido-2,3'-dideoxythymidine (AZT), polar solvents, in particular water, are used.

10 The anti-oxidizing agents used in the deproteinizing step are also known to those skilled in the art aiming to slow down the occurrence of oxidation reactions. Ascorbic acid may be cited as an example.

Drug concentration is measured by a suitable technique. Colorimetric and HPLC methods are preferred and well known (e.g., see McConnell, J.B., Smith, H., Davis, M., Williams, R. "Plasma rifampicin assay for an improved solvent extraction technique. Br J. Clin Pharmacol. 8:506-507. 1979; Acocella, G., Nonis, A., Gialdroni-Grassi, G., Grassi, C. "Comparative bioavailability of isoniazid, rifampicin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy". Am Rev Respir Dis. 138: 882-5. 1988.; Ishii, M., Agata, H. "Determination of rifampicin and its main metabolites in human plasma". J Chromatogr. 426: 412-6. 1988; Vanakoski, J., Mattila, M.J., Vainio, P., Idänpään-Heikkilä,

J.J. and Törnwall. "150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects". *Int J Clin Pharmacol Ther.* 33(9): 518-523. 1995; (see Frijus-Plessen N., Michaelis H.C., Foth H. e Kahl G.F. (1990). "Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography". *Chrombio.* Elsevier Science Publishers B.V. Amsterdam. 534: 101-107).

10 In the case of rifampicin and its metabolites, colorimetry is the most preferred when simplicity combined with accuracy is required. The rifampicin concentration is determined by spectrophotometric measurement of the supernatant organic phase at 340 nm. But the HPLC method may
15 also be used, and antioxidant substances can be added to the mixture of aqueous zinc sulphate, organic solvent and the body fluid to retard oxidation. Assay conditions, in this case, are also easily found in the related art, e.g. Frijus-Plessen *et al.* Figure 1 demonstrates the reproducibility and
20 accuracy of the method of the present invention through HPLC chromatograms.

Figures 2 and 3 show the reproducibility and accuracy of the method of the present invention illustrated by HPLC chromatograms of synthetic mixtures of rifampicin, 2',3'-
25 dideoxycytidine (ddC), 2',3'-dideoxyinosine (ddI), 3'-azido-

2,3'-dideoxythymidine (AZT) and itraconazole with body fluids.

To perform the rifampicin level detection method of the present invention, a kit containing standard solutions of aqueous zinc sulphate, organic solvent and body fluid, e.g. plasma standards, serum standards containing a known amount of rifampicin are provided. Procedure instructions may also be supplied. A typical kit of the invention consists of a solution of aqueous $ZnSO_4$ in a concentration from 0.1M to 5M, an organic solvent selected from the group of acetonitrile/2-propanol (1:1), benzene, toluene, dichloromethane, chloroform or its mixtures and a set of mixtures of plasma with rifampicin at several concentrations to obtain the standard curve for the user conditions. Particularly preferred are aqueous $ZnSO_4$ in a concentration of 0,2M to 1.0M and a mixture of $CH_3CN/CH_2CHOHCH_3$ (1:1) as the solvent.

Figures 4A and 4B and Table 1 refer to the standard curves of the colorimetric assay for mixtures of rifampicin and plasma at several concentrations ranging from 0,39 to 25 $\mu g/ml$ and $\lambda = 340$ nm. These standard curves for plasma extract had correlation coefficients of 0.9999 and the mean recoveries of rifampicin were at least 98%, corroborating the efficacy of the one step prior treatment of the present invention.

The method is also suitable for pharmacokinetics studies of rifampicin and its metabolites. Figure 5 shows the

rifampicin levels in plasma of two HIV positive patients with tuberculosis following oral administration of 600 mg of rifampicin, during a period of 24 hours subsequent to drug administration. The curve corresponding to the sample of one
5 of the patients is irregular because he is suffering from hepatic problems.

Table 1: Standard Curves of Rifampicin concentration in plasma

Concentration (µg/ml)	Absorbance							Mean	Standard Deviation	Variation Coefficient
	Curve 1	Curve 2	Curve 3	Curve 4	Curve 5	Curve 6	Curve 7			
0.39	0.013	0.012	0.014	0.012	0.009	0.008	0.011	0.01128571	0.00213809	0.00668153
0.78	0.022	0.021	0.019	0.021	0.020	0.019	0.021	0.02042857	0.00113389	5.55052723
1.56	0.042	0.040	0.042	0.046	0.040	0.043	0.043	0.04228571	0.00205866	4.86846088
3.00	0.096	0.088	0.088	0.094	0.090	0.087	0.097	0.09142857	0.00415761	4.54738507
6.25	0.189	0.180	0.191	0.191	0.178	0.181	0.185	0.18500000	0.00544671	2.9441684
12.50	0.382	0.368	0.370	0.365	0.375	0.368	0.367	0.37071429	0.00587975	1.58605901
25.00	0.770	0.748	0.768	0.724	0.775	0.746	0.732	0.75185714	0.0197689	2.62934297
Correlation Coefficient	0.99997559	0.99998962	0.99983102	0.99991144	0.99986669	0.99998607	0.99994411			

The advantages of the method of the present invention as compared with available methods described in literature are: accurate determination of the drug concentration in body fluid; faster determination of a selected drug level in a body fluid; simpler technique which is useful in smaller hospital centers and field laboratories; and lower costs permitting its use in public health systems.

The following examples are illustrative of the invention and represent preferred embodiments. Those skilled in the art may know, or be able to find using no more than routine experimentation, to employ other appropriate materials and techniques, such as the above mentioned extracting substances and measuring methods.

EXAMPLE 1

This example is to illustrate the determination of rifampicin level in plasma using a colorimetric assay.

500 μ l of plasma is mixed with 200 μ l of 0.5M $ZnSO_4$, 500 μ l of acetonitrile:2-propanol (1:1, v/v) and ascorbic acid 0,5 mg/ml in a vortex mixer and centrifuged for 3 minutes at 3,500 rpm. The spectrophotometric measurement of the supernatant organic phase permit the determination of rifampicin level in plasma.

This assay lasts 15 minutes. It is a very fast procedure as compared with other assays comprising many steps for rifampicin separation and does not require expensive equipment and specialized operating personel which are

necessary in more sophisticated techniques, such as HPLC.

EXAMPLE 2

The purpose of this example is to illustrate the determination of rifampicin level in plasma using a HPLC
5 procedure.

To 500 μ l of plasma, urine or saliva containing unknown amount of rifampicin are added 250 μ l of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0,5M, 1 ml of acetonitrile:2-propanol (1:1, v/v) and 0.5 mg/ml of ascorbic acid. The mixture is mechanically shaken for 5
10 minutes and, then centrifuged for 10 minutes at 3,500 rpm. A 20 μ l aliquot of the supernatant organic phase is injected into chromatographic column.

The chromatographic operating conditions are: the mobile phase consisting of 38% of B in A, where A = 0.1M KH_2PO_4 (10%
15 H_2O) and B = CH_3CN , pH = 3.5. The mixture is pumped at a constant flow-rate of about 2 ml/minute under a pressure of about 40 bar at room temperature, such as 30°C; the column is a RP 18 10 μ m 250 x 4.6 mm column; and the detection was carried out at 254 nm.

20 Calibration samples were prepared by measuring 20 μ l of rifampicin solution. Three to six samples containing 1.25 to 20 μ g/ml of rifampicin were prepared. The calibration graphs (peak area against time) were straight lines. The complete calibration was repeated every day. Retention time for
25 rifampicin was 4 minutes as showed in figure 1.

CLAIMS

1. Method of monitoring patient compliance and bioavailability of drugs contained in body fluids comprising
5 the following steps:

(a) mixing and shaking mechanically the body fluid with aqueous zinc sulfate solution, an appropriate solvent and, optionally an antioxidizing agent to precipitate proteins and strip off bound drug;

10 (b) centrifugating the mixture to obtain the separation of phases;

(c) recovering the supernatant and proceed to drug concentration measurement.

2. Method according to claim 1 wherein the concentration
15 of the aqueous zinc sulfate solution varies from 0.1M to 5.0M.

3. Method according to claim 3 wherein the concentration of the aqueous zinc sulfate solution varies from 0.2M to 1.0M.

20 4. Method according to claim 1 to 3 wherein the appropriate solvent is a polar, a nonpolar or mixtures thereof.

25 5. Method according to claim 4 wherein the nonpolar solvent is an organic solvent selected from the group consisting of acetonitrile/2-propanol (1:1), benzene, toluene, dichloromethane, chloroform or mixtures thereof.

6. Method according to claim 4 wherein the polar solvent is selected from the group consisting of water, alcohols or mixtures thereof.

7. Method according to claim 1 wherein ascorbic acid is the antioxidizing agent used in step (a).

8. Method according to claim 1 wherein the drug concentration measurement is carried out by using a colorimetric assay or a High-Performance Liquid Chromatography method.

9. Method according to claims 1, 3, 5 and 7 wherein the drug to be analyzed is rifampicin.

10. Method according to claim 1 wherein the drug to be analyzed is selected from the group of antimonials, itraconazole and proteinase or the reverse transcriptase inhibitors.

11. Method of monitoring patient compliance and bioavailability of rifampicin contained in body fluids comprising the following steps:

(a) mixing and shaking mechanically the body fluid with aqueous zinc sulfate solution, an organic solvent selected from the group consisting of acetonitrile/2-propanol (1:1), benzene, toluene, dichloromethane, chloroform or mixtures thereof and, optionally an antioxidizing agent to precipitate proteins and strip off bound drug;

(b) centrifugating the mixture to obtain the separation of phases;

(c) recovering the organic phase supernatant and proceed to drug concentration measurement by using a colorimetric assay or a High-Performance Liquid Chromatography method.

12. Method according to claim 11 wherein the concentration of the aqueous zinc sulfate solution varies from 0.1M to 5.0M.

13. Method according to claim 12 wherein the concentration of the aqueous zinc sulfate solution varies from 0.2M to 1.0M.

14. Method according to claims 11 and 13 wherein the solvent used in step (a) is acetonitrile/2-propanol (1:1).

15. Method according to claim 11 wherein ascorbic acid is the antioxidizing agent used in step (a).

16. Method according to claim 11 wherein the rifampicin concentration is determined through spectrophotometric measurement at 340 nm.

17. Kit for measuring rifampicin concentration in a body fluid containing the following components:

(a) a standard solution of aqueous zinc sulfate optionally having an antioxidizing agent;

(b) an organic solvent selected from the group consisting of acetonitrile/2-propanol (1:1), benzene, toluene, dichloromethane, chloroform or mixtures thereof;

(c) serum standards containing a known amount of rifampicin to prepare the standard curve for the user conditions.

18. Kit according to claim 17 wherein the concentration of the aqueous zinc sulfate solution varies from 0.1M to 5.0M.

19. Kit according to claim 18 wherein the concentration of the aqueous zinc sulfate solution varies from 0.2M to 1.0M.

20. Kit according to claim 17 wherein ascorbic acid is the antioxidizing agent.

21. Kit according to claim 17 wherein the organic solvent is acetonitrile/2-propanol (1:1).




Figure 1A




Figure 1B




Figure 1C




Figure 2




Figure 3




Figure 4A




Figure 4B




Figure 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/BR 99/00096

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: G 01 N 33/487, 33/50, 33/539, 33/573

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: G 01 N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 471295 A1 (ABBOTT LABORATORIES) 19 February 1992 (19.02.92), totality.	1-4, 6
Y		1-4,6,8,9,11-16
Y	ZHANG, W. et al. "Study on HPLC assay for the plasma concentration of rifampicin and its pharmacokinetics of microsphere formulation". Zhongguo Kangshengsu Zazhi 1996, 21(4), 273-276 (CH), Columbus, Ohio, USA, Chem. abstract, Vol. 126, No. 8, 24 February 1997 (24.02.97), page 1052, column 1, abstract No. 109002y.	1-4,6,8,9,11-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

24 March 2000 (24.03.00)

Date of mailing of the international search report

10 April 2000 (10.04.00)

Name and mailing address of the ISA/AT
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/200

Authorized officer

Schnass

Telephone No. 1/53424/217

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/BR 99/00096

Patent document cited in search report			Publication date	Patent family member(s)			Publication dat
DK	T3	471295	09-04-1996	AT	E	130095	15-11-1995
EP	A1	471295	19-02-1992	AU	A1	82472/91	20-02-1992
EP	B1	471295	08-11-1995	AU	B2	642522	21-10-1993
				CA	AA	2048314	16-02-1992
				DE	C0	69114403	14-12-1995
				DE	T2	69114403	05-06-1996
				ES	T3	2082059	16-03-1996
				GR	T3	3018907	31-05-1996
				JP	A2	4233460	21-08-1992
				US	A	5135875	04-08-1992